← Back to headlines
Merck Stock Analysis Highlights KEYTRUDA Growth
An analysis suggests Merck stock appears undervalued, citing the growth of its drug KEYTRUDA and a strong pipeline as factors offsetting near-term headwinds.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
Related Stories
Study Reveals Elderly More Vulnerable to Extreme Heat Than Previously Thought
2h ago
Nollywood Actor Ogogo Hassan's Daughters Seek Help for Father's Stage 4 Cancer
6h ago
Cancer Survivor Erin Races Against Time for Chance of Motherhood
6h ago
West Nile Fever Spreads in North Macedonia and Serbia, Causing Deaths
6h ago